跳转至内容
Merck
CN

P2116

Sigma-Aldrich

吡非尼酮

≥97% (HPLC)

登录查看公司和协议定价

别名:
5-甲基-1-苯基-2-(1H)-吡啶酮
经验公式(希尔记法):
C12H11NO
CAS号:
分子量:
185.22
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥97% (HPLC)

形式

powder

溶解性

H2O: >10 mg/mL at 60 °C (warming for 30 minutes)
DMSO: >20 mg/mL

创始人

Shionogi

SMILES字符串

O=C(C=CC(C)=C1)N1C2=CC=CC=C2

InChI

1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

InChI key

ISWRGOKTTBVCFA-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

吡非尼酮(5-甲基-1-苯基-2-[1H]-吡啶酮)是合成的吡啶 衍生物。

应用

吡非尼酮用于:
  • 作为兔的术后滴眼剂,分析其抗纤维化作用,改进青光眼滤过手术
  • 作为抗瘢痕形成剂,检查其是否影响兔植入青光眼引流装置(GDD)后的异物反应
  • 在人眼眶成纤维细胞(hOF)原代培养物中测试其抗纤维化潜力
  • 作为肿瘤坏死因子(TNFα)抑制剂,研究其在缺氧中的作用

生化/生理作用

吡非尼酮可抑制胶原生成和成纤维细胞增殖。在多种肺纤维化动物模型和临床试验中显示出抗纤维化和抗炎属性。
吡非尼酮用于治疗特发性肺纤维化(IPF)。有助于减少肺功能下降引起的衰弱,延长无进展生存期。吡非尼酮可抑制人Tenon′s 囊成纤维细胞胶原蛋白的增殖和收缩。

特点和优势

该化合物由 Shionogi 开发。如需浏览其他制药公司开发的化合物和批准的药物/候选药物列表,请点击此处

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Peyman Bizargity et al.
Transplantation, 94(2), 114-122 (2012-06-30)
Pirfenidone (PFD) is an antifibrotic agent with beneficial effects on proinflammatory disorders. In this study, we further investigated PFD and long-acting form, "deuterated PFD," immune-modulating properties by evaluating their effects on mouse dendritic cells (DCs). The effects of PFD on
Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro
Stahnke T, et al.
Testing, 12(2), e0172592-e0172592 (2017)
Natalie J Carter
Drugs, 71(13), 1721-1732 (2011-09-10)
Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day for 72 weeks administered to patients with IPF was associated with a significantly lower
Arata Azuma
Therapeutic advances in respiratory disease, 6(2), 107-114 (2012-02-16)
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3-5 years, and the
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster L H, et al.
European Respiratory Review, 26(146), 170057-170057 (2017)

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门